

Tirbanibulin Therapeutic Cheat Sheet

COMPILED BY: MICHAEL J. VISCONTI, DO | REVIEWED BY: DAVID ALTMAN, MD

TRADE NAMES:

- > Klisyri®

INDICATION:

- > Actinic keratosis or keratoses located on the face and/or scalp

DOSING/REGIMEN:

- > Ointment (1%)
- > Once per day for five days
*Short regimen may improve adherence and patient satisfaction
- > Do not apply under occlusion

EVIDENCE:

- > Phase 2 Clinical Trial:
 - Complete clearance by day 57 in 43% of patients
- > Phase 3 Clinical Trial (Pooled):
 - Complete clearance in 49% of patients (versus 9% with vehicle alone)

*Comparative studies with other treatments (i.e., 5-fluorouracil) do not yet exist

CONTRAINDICATIONS:

- > Careful monitoring for allergy to propylene glycol
- > Animal studies reveal teratogenic effects with oral administration

MONITORING:


- > Ensure occlusion is not being utilized after application
- > Ensure ocular injuries or adverse effects are not sustained from cross-contamination

REFERENCES

1. Kempers S, DuBois J, Forman S, et al. Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results. *J Drugs Dermatol.* 2020;19:1093-1100.
2. Dao DD, Sahni VN, Sahni DR, et al. 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses. *Ann Pharmacother.* 2022;56:494-500.
3. Kumar A, Jaggi AS, Singh N. Pharmacology of Src family kinases and therapeutic implications of their modulators. *Fundam Clin Pharmacol.* 2015;29:115-130.
4. Gilaberte Y, Fernández-Figueras MT. Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis. *Actas Dermosifiliogr.* 2022;113:58-66.
5. Klisyri ointment. Package insert. Almirall, LLC. Accessed November 1, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf

DRUG CLASS/MECHANISM OF ACTION:

- > Inhibits tubulin polymerization > blocking cell division
- > Disrupts Src kinase signaling > blocks cell growth



ADVERSE EFFECTS:

- > Allergic contact dermatitis (ointment contains propylene glycol)
- > Non-allergic cutaneous reactions (crusting, ulceration/erosion, erythema, vesiculation, swelling)
- > Application site pain and/or pruritus
- > Ocular irritation (counsel on thorough rinsing of hands after application)